Skip to main content

Scientists Discover Way to Send Information into Black Holes Without Using Energy

3 comments

World’s First Personalized mRNA Cancer Vaccine Succeeds in Phase 3 Trial, Marking a New Era in Cancer Treatment

For decades, cancer treatment has largely followed a common approach: identify the type of cancer and then give patients treatments designed for that disease. But a new generation of cancer therapy is moving toward something much more personal—treatment designed around the unique genetic features of an individual patient’s tumor.

Now, pharmaceutical and biotechnology company Moderna, working with Merck, has reported encouraging Phase 3 results for a personalized mRNA cancer vaccine called intismeran autogene, also known as mRNA-4157/V940. The therapy is designed specifically for each patient and can target up to 34 tumor-specific mutations.

The latest results could represent an important step toward making personalized cancer vaccines a practical treatment option, particularly for people with high-risk melanoma.

A Cancer Vaccine Built for Each Patient

Unlike traditional vaccines, which are generally designed to protect people against the same infectious disease, intismeran is created around the individual biology of a patient's cancer.

The process begins after doctors surgically remove a patient's tumor. Scientists analyze the tumor's genetic mutations and look for unusual proteins, known as neoantigens, that are found on cancer cells.

These neoantigens can act like identifying markers. Because they are associated with the patient's tumor, they may provide the immune system with targets that distinguish cancer cells from healthy cells.

Researchers then select a group of promising neoantigens and create a personalized mRNA sequence. Intismeran can contain instructions for up to 34 of these targets.

The resulting treatment is therefore not exactly the same for every patient. Instead, it is designed according to the genetic characteristics of that person's tumor.

How Does the mRNA Vaccine Work?

The basic idea behind the treatment is relatively simple, even though the technology behind it is highly sophisticated.

mRNA, or messenger RNA, carries biological instructions that cells can use to produce specific proteins. In the case of intismeran, the synthetic mRNA provides instructions related to the selected tumor neoantigens.

The therapy is delivered using lipid nanoparticles, which help transport the mRNA into cells.

Once the instructions are processed, the immune system is exposed to the selected cancer-related targets. The goal is to train immune cells—particularly T cells—to recognize these targets.

If cancer cells carrying the same mutations remain in the body, the trained immune system may be better prepared to identify and attack them.

This is particularly important after surgery. Even when surgeons successfully remove visible melanoma, microscopic cancer cells can sometimes remain elsewhere in the body. These remaining cells may eventually grow and cause the disease to return.

The personalized vaccine is intended to help the immune system find and destroy those hidden cancer cells.

Why Keytruda Is Important

In the Phase 3 study, intismeran was not tested alone. It was combined with pembrolizumab, better known by the brand name Keytruda, an immunotherapy developed by Merck.

Keytruda works by blocking the interaction between the PD-1 receptor and its ligands. This can remove an important "brake" from the immune system, allowing T cells to remain active against cancer cells.

The combination therefore uses two complementary strategies.

Intismeran aims to give the immune system highly specific targets, while pembrolizumab helps keep immune cells active.

The researchers hope that this combination can create a stronger and more precise immune response against melanoma.

Large Phase 3 Trial Included More Than 1,100 Patients

The Phase 3 trial included 1,137 people with cutaneous melanoma. Participants had stage IIB, IIC, III or IV disease and had undergone complete surgical removal of their tumors.

Patients were randomly divided into two groups in a 2:1 ratio.

One group received personalized intismeran together with Keytruda, while the other received Keytruda alone.

Intismeran was administered every three weeks for up to nine doses. Keytruda was given every six weeks, with treatment continuing for approximately one year.

The main purpose was to determine whether adding the personalized vaccine could improve outcomes for patients at significant risk of their melanoma returning.

Encouraging Results From the Trial

According to Moderna and Merck, the Phase 3 trial achieved its primary goals.

Interim results showed statistically significant and clinically meaningful improvements in both major endpoints when the personalized vaccine was combined with Keytruda compared with Keytruda alone.

The companies have not yet released the complete Phase 3 dataset. Researchers will continue following the participants to determine how long the benefits last and how the treatment affects long-term survival.

Importantly, the companies also reported that no new safety concerns were identified. The safety profile of the combination was consistent with earlier clinical studies.

The complete findings are expected to be presented at a future medical meeting, where researchers can provide more detailed information about the results.

Earlier Results Had Already Raised Hope

The Phase 3 success follows promising findings from an earlier Phase 2b study.

After five years of follow-up, the combination of intismeran and Keytruda was reported to reduce the risk of melanoma recurrence or death by 49% compared with Keytruda alone.

It also reduced the risk of the cancer spreading to other parts of the body or death by 59%.

These earlier findings provided an important reason to move the technology into a much larger Phase 3 trial.

The latest results now strengthen the possibility that personalized mRNA cancer vaccines could become part of future cancer treatment.

Could This Technology Treat Other Cancers?

Melanoma may only be the beginning.

Moderna and Merck are already studying the personalized approach in additional clinical trials involving cancers such as lung, bladder and kidney cancer.

The underlying concept is potentially adaptable because every tumor contains its own collection of genetic changes. If researchers can accurately identify mutations that produce useful immune targets, they may be able to create personalized treatments for different cancer types.

However, significant challenges remain.

Producing a different vaccine for every patient is much more complicated than manufacturing a standard vaccine. Doctors and laboratories must collect tumor samples, sequence the cancer, identify suitable neoantigens, design the mRNA treatment and manufacture the personalized dose.

Speed and accuracy will therefore be extremely important.

A New Direction for Cancer Medicine

The significance of intismeran goes beyond melanoma.

For years, researchers have dreamed of treatments that could use a patient's own tumor mutations to guide the immune system. mRNA technology could provide a flexible way to turn that idea into a personalized therapy.

The approach also represents a major shift in how scientists think about cancer treatment. Instead of treating every patient's cancer in exactly the same way, doctors could increasingly use the genetic fingerprint of an individual tumor to guide therapy.

Georgina Long, PhD, the study's principal investigator, described the findings as a landmark moment for adjuvant melanoma treatment, highlighting the potential for the combination to help patients remain cancer-free for longer.

Still, it is important to remember that a successful Phase 3 trial does not automatically mean the treatment is immediately available to everyone. Regulators must review the complete clinical data before deciding whether the therapy should receive approval.

If approved, however, intismeran could mark an important milestone in personalized cancer medicine.

The same mRNA technology that became widely known during the COVID-19 pandemic is now being explored for a very different purpose: teaching the immune system to recognize an individual's own cancer.

The future of cancer treatment may therefore become less about finding one medicine for millions of patients—and more about creating the right medicine for one patient at a time.

Comments

Post a Comment

Popular

Scientists Discover Way to Send Information into Black Holes Without Using Energy

For years, scientists believed that adding even one qubit (a unit of quantum information) to a black hole needed energy. This was based on the idea that a black hole’s entropy must increase with more information, which means it must gain energy. But a new study by Jonah Kudler-Flam and Geoff Penington changes that thinking. They found that quantum information can be teleported into a black hole without adding energy or increasing entropy . This works through a process called black hole decoherence , where “soft” radiation — very low-energy signals — carry information into the black hole. In their method, the qubit enters the black hole while a new pair of entangled particles (like Hawking radiation) is created. This keeps the total information balanced, so there's no violation of the laws of physics. The energy cost only shows up when information is erased from the outside — these are called zerobits . According to Landauer’s principle, erasing information always needs energy. But ...
3 comments
Read more

A New Type of Wormhole Could Slowly Become Stable Over Time, Scientists Suggest

For many years, wormholes have captured the imagination of scientists and science fiction fans. They are often shown as magical tunnels through space that can connect two faraway places in the universe. If wormholes really exist, they could one day make it possible to travel huge distances in a very short time. But there is one big problem—no one has ever found a real wormhole. They remain only theoretical objects predicted by the mathematics of Einstein's theory of general relativity. Even though they have never been observed, physicists continue studying them because they help us understand the limits of gravity and spacetime. Now, researchers Ditta and Channuie have proposed a new model of a time-dependent traversable wormhole . Unlike many earlier models, their wormhole is not completely still. Instead, it changes with time because energy flows through it. As this flow slowly fades away, the wormhole naturally becomes stable. Their study offers a new and simple way to understan...
Post a Comment
Read more

Black Holes That Never Dies

Black holes are powerful objects in space with gravity so strong that nothing can escape them. In the 1970s, Stephen Hawking showed that black holes can slowly lose energy by giving off tiny particles. This process is called Hawking radiation . Over time, the black hole gets smaller and hotter, and in the end, it disappears completely. But new research by Menezes and his team shows something different. Using a theory called Loop Quantum Gravity (LQG) , they studied black holes with quantum corrections. In their model, the black hole does not vanish completely. Instead, it stops shrinking when it reaches a very small size. This leftover is called a black hole remnant . They also studied something called grey-body factors , which affect how much energy escapes from a black hole. Their findings show that the black hole cools down and stops losing mass once it reaches a minimum mass . This new model removes the idea of a “singularity” at the center of the black hole and gives us a better ...
Post a Comment
Read more